Opinion|Videos|May 2, 2024
Physician Awareness of Cognitive Dysfunction in Schizophrenia
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, discuss awareness among physicians of the concept of cognitive impairment associated with schizophrenia and detail unmet needs, including the lack of approved therapies, measurement tools, and access to cognitive remediation.
Advertisement
Episodes in this series
Advertisement
Related to this article
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
3
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
4
FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies
5